TYK MEDICINES-B (02410) announced that its investigational Class 1 new drug, Aidosertinib Mesylate Tablets (TY-9591 tablets), has been included in the Priority Review品种 list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The proposed indication for Aidosertinib Mesylate Tablets (TY-9591 tablets) is the first-line treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, accompanied by CNS metastases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments